# A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease

Study · id `cardio:ct-nct05205499` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05205499](<https://clinicaltrials.gov/study/NCT05205499>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05205499

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1059 participants.

## Technical summary

Registry record NCT05205499. Allocation not applicable; no masking; primary purpose treatment. Start 2022-03-10 (actual); primary completion 2024-07-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1059 participants (enrolled count; ClinicalTrials.gov record NCT05205499, source copy `cardio:ctgov-nct05205499-2025-12-10`, retrieved 2026-10-26)
- Started: 2022-03-10 (actual) (ClinicalTrials.gov record NCT05205499, source copy `cardio:ctgov-nct05205499-2025-12-10`, retrieved 2026-10-26)
- Primary completion: 2024-07-01 (actual) (ClinicalTrials.gov record NCT05205499, source copy `cardio:ctgov-nct05205499-2025-12-10`, retrieved 2026-10-26)
- Completion: 2028-08 (anticipated) (ClinicalTrials.gov record NCT05205499, source copy `cardio:ctgov-nct05205499-2025-12-10`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05205499, source copy `cardio:ctgov-nct05205499-2025-12-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05205499-2025-12-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease
- Acronym: IRONMAN-III
- Condition: Coronary Artery Disease
- Intervention (Device): Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System
- Lead sponsor: Biotyx Medical (Shenzhen) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Biotyx Medical (Shenzhen) Co., Ltd. (`cardio:org-biotyx-medical-shenzhen-co-ltd`)

## Provenance

Content hash: 7edb5cfdf7bb7b6b18dfe7f6e25df247ffdf31e291b7781b4231c8e5e70fcd6f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
